Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Multiple Sclerosis

Free Subscription Articles published in Neurology Retrieve available abstracts of 223 articles: HTML format

Single Articles

June 2024
1. PALLADINO R, Monasta L
   Estimating the Prevalence and Burden of Multiple Sclerosis in China Using the Global Burden of Disease Study: Challenges and Future Directions.
   Neurology. 2024;102:e209521.
   PubMed    
   
   
   
2. ZHANG C, Liu W, Wang L, Wang F, et al
   Prevalence and Burden of Multiple Sclerosis in China, 1990-2019: Findings From the Global Burden of Disease Study 2019.
   Neurology. 2024;102:e209351.
   PubMed     Abstract available
   
   
   May 2024
3. CACCIAGUERRA L, Abdel-Mannan O, Champsas D, Mankad K, et al
   Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
   Neurology. 2024;102:e209303.
   PubMed     Abstract available
   
   
   
4. SILBERMANN E, Spain RI
   Serum Neurofilament Light Chain for Multiple Sclerosis Relapses: Too Little Too Late?
   Neurology. 2024;102:e209456.
   PubMed    
   
   
   
5. FOX RJ, Cree BAC, de Seze J, Gold R, et al
   Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
   Neurology. 2024;102:e209357.
   PubMed     Abstract available
   
   
   
6. MICHAELSON NM
   Right Brain: The Unraveling.
   Neurology. 2024;102:e209492.
   PubMed     Abstract available
   
   
   
7. VYAS MV, Kapral MK, Alonzo R, Fang J, et al
   Proportion of Life Spent in Canada and the Incidence of Multiple Sclerosis in Permanent Immigrants.
   Neurology. 2024;102:e209350.
   PubMed     Abstract available
   
   
   April 2024
8. 
   Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study.
   Neurology. 2024;102:e209214.
   PubMed    
   
   
   
9. OLIVE-CIRERA G, Bruijstens AL, Fonseca EG, Chen LW, et al
   MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
   Neurology. 2024;102:e209199.
   PubMed     Abstract available
   
   
   
10. SPELMAN T, Simoneau G, Hyde R, Kuhelj R, et al
    Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
    Neurology. 2024;102:e208114.
    PubMed     Abstract available
    
    
    March 2024
11. MARRIE RA, Salter A
    Off-Road Testing: Outcome Reporting Bias in Multiple Sclerosis Trials.
    Neurology. 2024;102:e208099.
    PubMed    
    
    
    
12. LEMMENS CMC, van Amerongen S, Strijbis EM, Killestein J, et al
    Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e208032.
    PubMed     Abstract available
    
    
    
13. 
    Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209252.
    PubMed    
    
    
    
14. BOURDETTE D, Wooliscroft L
    The Challenges of Treating Late-Onset Multiple Sclerosis.
    Neurology. 2024;102:e209146.
    PubMed    
    
    
    
15. MOURESAN EF, Mentesidou E, Berglund A, Mckay KA, et al
    Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Neurology. 2024;102:e208051.
    PubMed     Abstract available
    
    
    
16. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
    Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;102:e209135.
    PubMed     Abstract available
    
    
    
17. CHARD DT
    Chronically Active Lesions as a Trial Outcome in Multiple Sclerosis: A New Perspective on an Old Foe.
    Neurology. 2024;102:e209246.
    PubMed    
    
    
    
18. ARNOLD DL, Elliott C, Martin EC, Hyvert Y, et al
    Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Neurology. 2024;102:e208058.
    PubMed     Abstract available
    
    
    
19. PAPP V, Magyari M, Moller S, Sellebjerg F, et al
    Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort.
    Neurology. 2024;102:e209147.
    PubMed     Abstract available
    
    
    February 2024
20. RADZIK AM, Amezcua L, Anderson A, Gilmore S, et al
    Disparities by Race in Pregnancy Care and Clinical Outcomes in Women With Multiple Sclerosis: A Diverse Multicenter Cohort.
    Neurology. 2024;102:e208100.
    PubMed     Abstract available
    
    
    
21. GALBUSERA R, Bahn E, Weigel M, Cagol A, et al
    Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e207966.
    PubMed     Abstract available
    
    
    
22. NG HS, Zhu F, Zhao Y, Yao S, et al
    Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis.
    Neurology. 2024;102:e208006.
    PubMed     Abstract available
    
    
    
23. BRIDGE F, Brotherton J, Stankovich J, Sanfilippo PG, et al
    Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
    Neurology. 2024;102:e208059.
    PubMed     Abstract available
    
    
    January 2024
24. GIBSON S, Mcgraw C
    Teaching NeuroImage: Cryptococcus in a Woman With Multiple Sclerosis on Fingolimod.
    Neurology. 2024;102:e208027.
    PubMed     Abstract available
    
    
    
25. MCGINLEY MP, Harvey T, Lopez R, Ontaneda D, et al
    Geographic Disparities in Access to Neurologists and Multiple Sclerosis Care in the United States.
    Neurology. 2024;102:e207916.
    PubMed     Abstract available
    
    
    
26. LANGER-GOULD A, Sotirchos ES, Bourdette D
    Rituximab for Multiple Sclerosis.
    Neurology. 2024;102:e208063.
    PubMed     Abstract available
    
    
    
27. GALETTA S, Brownlee W
    Assignment Completed.
    Neurology. 2024;102:e207913.
    PubMed     Abstract available
    
    
    
28. TUR C, Rocca MA
    Progression Independent of Relapse Activity in Multiple Sclerosis.
    Neurology. 2024;102:e207936.
    PubMed     Abstract available
    
    
    
29. VIDAL-JORDANA A, Rovira A, Calderon W, Arrambide G, et al
    Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria.
    Neurology. 2024;102:e200805.
    PubMed     Abstract available
    
    
    
30. CAGOL A, Benkert P, Melie-Garcia L, Schaedelin SA, et al
    Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
    Neurology. 2024;102:e207768.
    PubMed     Abstract available
    
    
    December 2023
31. ROLLOT F, Uhry Z, Dantony E, Vukusic S, et al
    Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality.
    Neurology. 2023;101:e2483-e2496.
    PubMed     Abstract available
    
    
    
32. GUINEBRETIERE O, Nedelec T, Gantzer L, Lekens BB, et al
    Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis.
    Neurology. 2023 Dec 5:10.1212/WNL.0000000000207981.
    PubMed     Abstract available
    
    
    October 2023
33. SOTIRCHOS ES, Hu C, Smith MD, Lord HN, et al
    Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957.
    PubMed     Abstract available
    
    
    September 2023
34. COBO-CALVO A, Tur C, Otero-Romero S, Carbonell-Mirabent P, et al
    Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.
    Neurology. 2023;101:e1280-e1292.
    PubMed     Abstract available
    
    
    
35. PALLADINO R, Strijbis EM
    How Far Are We in Translating the Multiple Sclerosis Prodromes in Clinical Practice?
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207989.
    PubMed    
    
    
    
36. CHERTCOFF AS, Yusuf F, Zhu F, Evans C, et al
    Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207843.
    PubMed     Abstract available
    
    
    
37. HUPPKE BM, Reinert M, Hummel-Abmeier H, Stark W, et al
    Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207791.
    PubMed     Abstract available
    
    
    
38. ALMRAMHI MM, Finan C, Storm CS, Schmidt AF, et al
    Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207777.
    PubMed     Abstract available
    
    
    
39. BUYUKKURT A, Harroud A
    The Potential to Inform Statin Use in Multiple Sclerosis Through Human Genetics [re: WNL-2023-000524].
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207773.
    PubMed    
    
    
    August 2023
40. BSTEH G, Hegen H, Altmann P, Auer M, et al
    Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis.
    Neurology. 2023;101:e784-e793.
    PubMed     Abstract available
    
    
    
41. GRAVES JS
    Cell Specific Aging in Multiple Sclerosis.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207679.
    PubMed    
    
    
    
42. MALTBY V, Xavier A, Ewing E, Campagna MP, et al
    Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207489.
    PubMed     Abstract available
    
    
    July 2023
43. FADDA G, Cardenas de la Parra A, O'Mahony J, Waters P, et al
    Deviation From Normative Whole Brain and Deep Gray Matter Growth in Children With MOGAD, MS, and Monophasic Seronegative Demyelination.
    Neurology. 2023;101:e425-e437.
    PubMed     Abstract available
    
    
    
44. COUSTAL C, Goulabchand R, Labauge P, Guilpain P, et al
    Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207609.
    PubMed     Abstract available
    
    
    
45. SCHWEITZER F, Laurent S, Cortese I, Fink GR, et al
    Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207622.
    PubMed     Abstract available
    
    
    
46. LONGBRAKE E, Kalincik T
    Early Treatment for Multiple Sclerosis: Time Is Brain.
    Neurology. 2023 Jul 19:10.1212/WNL.0000000000207754.
    PubMed    
    
    
    
47. EHRHARDT H, Lambe J, Moussa H, Vasileiou ES, et al
    Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post-Hoc Analyses of the SPRINT-MS Trial.
    Neurology. 2023 Jul 17:10.1212/WNL.0000000000207551.
    PubMed     Abstract available
    
    
    
48. BENNETT JL
    Sprinting to the Finish: Optical Coherence Tomography, Retinal Atrophy, and Neurodegeneration in Progressive Multiple Sclerosis.
    Neurology. 2023 Jul 17:10.1212/WNL.0000000000207607.
    PubMed    
    
    
    
49. JAIN A, Arena VP, Steigerwald C, Borja MJ, et al
    Pearls and Oy-sters: CSF1R-Related Leukoencephalopathy With Spinal Cord Lesions Mimicking Multiple Sclerosis.
    Neurology. 2023 Jul 5:10.1212/WNL.0000000000207502.
    PubMed     Abstract available
    
    
    
50. TOOSY AT, Vidal-Jordana A
    Is the Optic Nerve Overdue as a Criterion to Support the Diagnosis of Multiple Sclerosis?
    Neurology. 2023 Jul 3:10.1212/WNL.0000000000207625.
    PubMed    
    
    
    June 2023
51. KOCH-HENRIKSEN N
    Worldwide Disparity in the Effectiveness of the Diagnostic Process in Multiple Sclerosis.
    Neurology. 2023 Jun 30:10.1212/WNL.0000000000207530.
    PubMed    
    
    
    
52. SOLOMON AJ, Marrie RA, Viswanathan S, Correale J, et al
    Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third Edition.
    Neurology. 2023 Jun 15:10.1212/WNL.0000000000207481.
    PubMed     Abstract available
    
    
    
53. ROTSTEIN D, Schneider R
    A Birth Year Cohort and What It Can Reveal About Lipid Mediators as Putative Biomarkers of Progression in Multiple Sclerosis.
    Neurology. 2023 Jun 8:10.1212/WNL.0000000000207605.
    PubMed    
    
    
    
54. BROOS JY, Loonstra FC, de Ruiter LRJ, Gouda MMTEE, et al
    Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis.
    Neurology. 2023 Jun 8:10.1212/WNL.0000000000207459.
    PubMed     Abstract available
    
    
    
55. KOWALEC K, Fitzgerald KC, Salter A, Dolovich C, et al
    Polygenicity of Comorbid Depression in Multiple Sclerosis.
    Neurology. 2023 Jun 8:10.1212/WNL.0000000000207457.
    PubMed     Abstract available
    
    
    April 2023
56. LUSK JB, Hoffman MN, Clark AG, Bae J, et al
    Association Between Neighborhood Socioeconomic Status and 30-Day Mortality and Readmission for Patients With Common Neurologic Conditions.
    Neurology. 2023;100:e1776-e1786.
    PubMed     Abstract available
    
    
    
57. LEAVITT VM
    The Mismeasure of Change: Better Cognitive Measurement Instruments are Urgently Needed for Multiple Sclerosis Research.
    Neurology. 2023 Apr 18:10.1212/WNL.0000000000207431.
    PubMed    
    
    
    
58. CASTROGIOVANNI N, Mostert J, Repovic P, Bowen JD, et al
    Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset.
    Neurology. 2023 Apr 18:10.1212/WNL.0000000000207301.
    PubMed     Abstract available
    
    
    March 2023
59. CARTA S, Cobo Calvo A, Armangue T, Saiz A, et al
    Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study.
    Neurology. 2023;100:e1095-e1108.
    PubMed     Abstract available
    
    
    January 2023
60. PATIL SA, Grossman S, Kenney R, Balcer LJ, et al
    Where's the Vision? The Importance of Visual Outcomes in Neurologic Disorders: The 2021 H. Houston Merritt Lecture.
    Neurology. 2023;100:244-253.
    PubMed     Abstract available
    
    
    
61. CACCIAGUERRA L, Morris P, Tobin WO, Chen JJ, et al
    Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2023 Jan 23:10.1212/WNL.0000000000206820.
    PubMed     Abstract available
    
    
    
62. HORTON MK, Robinson SC, Shao X, Quach H, et al
    A Cross-Trait, Mendelian Randomization Study to Investigate Whether Migraine Is a Risk Factor for Multiple Sclerosis.
    Neurology. 2023 Jan 11:10.1212/WNL.0000000000206791.
    PubMed     Abstract available
    
    
    December 2022
63. BORDEA E, Hunter RM
    Excess Treatment Costs of Multiple Sclerosis: What Can We Learn From Longitudinal Population-Based Data?
    Neurology. 2022 Dec 23:10.1212/WNL.0000000000206804.
    PubMed    
    
    
    
64. GAVOILLE A, Rollot F, Casey R, Debouverie M, et al
    Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.
    Neurology. 2022 Dec 23:10.1212/WNL.0000000000206774.
    PubMed     Abstract available
    
    
    
65. BERGSLAND N, Dwyer MG, Jakimovski D, Tavazzi E, et al
    Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis.
    Neurology. 2022 Dec 21:10.1212/WNL.0000000000201608.
    PubMed     Abstract available
    
    
    
66. BOFFA G, Signori A, Massacesi L, Mariottini A, et al
    Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
    Neurology. 2022 Dec 21:10.1212/WNL.0000000000206750.
    PubMed     Abstract available
    
    
    
67. MULLER J, Noteboom S, Granziera C, Schoonheim MM, et al
    Understanding the Role of the Choroid Plexus in Multiple Sclerosis as an MRI Biomarker of Disease Activity.
    Neurology. 2022 Dec 21:10.1212/WNL.0000000000206806.
    PubMed    
    
    
    
68. MULLER-JENSEN L, Kriedemann H, Anvari K, Huehnchen P, et al
    Complicated Monkeypox Infection in a Patient With Multiple Sclerosis and Fingolimod Treatment.
    Neurology. 2022 Dec 20:10.1212/WNL.0000000000206743.
    PubMed    
    
    
    November 2022
69. KHAKBAN A, Llorian ER, Michaux KD, Patten SB, et al
    Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based Cohort Study From 2001 to 2020 in British Columbia, Canada.
    Neurology. 2022 Nov 30:10.1212/WNL.0000000000201645.
    PubMed     Abstract available
    
    
    
70. ZIEMSSEN T
    Reader Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use.
    Neurology. 2022;99:868.
    PubMed    
    
    
    
71. PARNETTI L, Gaetani L
    Author Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use.
    Neurology. 2022;99:869.
    PubMed    
    
    
    
72. LEWIS A, Galetta S
    Editors' Note: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022;99:818.
    PubMed    
    
    
    
73. BEBO BF
    Author Response: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022;99:819.
    PubMed    
    
    
    
74. VARGAS WS
    Reader Response: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022;99:818-819.
    PubMed    
    
    
    October 2022
75. LI L, Avina-Zubieta JA, Bernstein CN, Kaplan GG, et al
    Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor Alpha in Four Canadian Provinces: A Population-Based Study.
    Neurology. 2022 Oct 28. pii: WNL.0000000000201472.
    PubMed     Abstract available
    
    
    
76. 
    Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
    Neurology. 2022 Oct 28. pii: WNL.0000000000201391.
    PubMed    
    
    
    
77. STRIJBIS EMM, Koch MW
    TNF Alfa Blockers and the Risk of Multiple Sclerosis.
    Neurology. 2022 Oct 28. pii: WNL.0000000000201629.
    PubMed    
    
    
    
78. DOBSON R, Bove R
    In Vitro Fertilization and Multiple Sclerosis: Evolving Treatments and Reducing Relapse Risk.
    Neurology. 2022;99:737-738.
    PubMed    
    
    
    
79. SNETSELAAR L, Cheek JJ, Fox SS, Healy HS, et al
    Efficacy of Diet on Fatigue and Quality of Life in Multiple Sclerosis: A Systematic Review and Network Meta-analysis of Randomized Trials.
    Neurology. 2022 Oct 18. pii: WNL.0000000000201371.
    PubMed     Abstract available
    
    
    
80. SPAIN R, Piccio L, Langer-Gould AM
    The Role of Diet in Multiple Sclerosis: Food for Thought.
    Neurology. 2022 Oct 18. pii: WNL.0000000000201565.
    PubMed    
    
    
    
81. DUBESSY AL, Stankoff B, Arnulf I
    Author Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2022;99:727.
    PubMed    
    
    
    
82. SIEGLER JE, Galetta S
    Editors' Note: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2022;99:726.
    PubMed    
    
    
    
83. SPARASCI D, Zecca C, Gobbi C, Manconi M, et al
    Reader Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2022;99:726-727.
    PubMed    
    
    
    
84. MURPHY OC, Calabresi PA, Gold DR
    Teaching Video NeuroImage: Dramatic Response to Topiramate in Acquired Pendular Nystagmus From Multiple Sclerosis.
    Neurology. 2022 Oct 11. pii: WNL.0000000000201452.
    PubMed    
    
    
    
85. GANESH A, Galetta S
    Editors' Note: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022;99:630.
    PubMed    
    
    
    
86. BARRO C
    Reader Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022;99:630-631.
    PubMed    
    
    
    
87. LEPPERT D, Kropshofer H, Haring D, Dahlke F, et al
    Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022;99:631.
    PubMed    
    
    
    
88. CORTESE R, Carrasco FP, Tur C, Bianchi A, et al
    Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
    Neurology. 2022 Oct 3. pii: WNL.0000000000201465.
    PubMed     Abstract available
    
    
    September 2022
89. B SYC-MAZUREK S, Chen JJ, Morris P, Sechi E, et al
    Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease.
    Neurology. 2022 Sep 29. pii: WNL.0000000000201263.
    PubMed     Abstract available
    
    
    
90. CAROTENUTO A, Valsasina P, Schoonheim MM, Geurts JJ, et al
    Investigating Functional Network Abnormalities and Associations With Disability in Multiple Sclerosis.
    Neurology. 2022 Sep 12. pii: WNL.0000000000201264.
    PubMed     Abstract available
    
    
    August 2022
91. CORDANO C, Nourbakhsh B, Yiu HH, Papinutto N, et al
    Differences in Age-Related Retinal and Cortical Atrophy Rates in Multiple Sclerosis.
    Neurology. 2022 Aug 29. pii: WNL.0000000000200977.
    PubMed     Abstract available
    
    
    
92. VILLOSLADA P, Llufriu S
    Preventing Neurodegeneration in Multiple Sclerosis Is Required From the Earliest Stages of the Disease.
    Neurology. 2022 Aug 29. pii: WNL.0000000000201223.
    PubMed    
    
    
    
93. HWANG S, Garcia-Dominguez MA, Fitzgerald KC, Saylor DR, et al
    Association of Multiple Sclerosis Prevalence With Sociodemographic, Health Systems, and Lifestyle Factors on a National and Regional Level.
    Neurology. 2022 Aug 24. pii: WNL.0000000000200962.
    PubMed     Abstract available
    
    
    
94. BRENTON JN, Florenzo B, Koshiya H, Min S, et al
    Six-Minute Walk as a Measure of Walking Capacity and Endurance in Patients With Pediatric-Onset Multiple Sclerosis.
    Neurology. 2022 Aug 19. pii: WNL.0000000000201098.
    PubMed     Abstract available
    
    
    
95. ROOS I, Malpas C, Leray E, Casey R, et al
    Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022 Aug 17. pii: WNL.0000000000201029.
    PubMed     Abstract available
    
    
    
96. DOBSON R, Bove R
    IVF and Multiple Sclerosis: Evolving Treatments and Reducing Relapse Risk.
    Neurology. 2022 Aug 11. pii: WNL.0000000000201242.
    PubMed    
    
    
    
97. MAINGUY M, Tillaut H, Degremont A, Le Page E, et al
    Assessing the Risk of Relapse Requiring Corticosteroids After In Vitro Fertilization in Women With Multiple Sclerosis.
    Neurology. 2022 Aug 11. pii: WNL.0000000000201027.
    PubMed     Abstract available
    
    
    
98. O'MAHONY J, Salter A, Ciftci B, Fox RJ, et al
    Physical and Mental Health-Related Quality of Life Trajectories Among People With Multiple Sclerosis.
    Neurology. 2022 Aug 10. pii: WNL.0000000000200931.
    PubMed     Abstract available
    
    
    
99. BSTEH G, Krajnc N, Riedl K, Altmann P, et al
    Retinal Layer Thinning After Optic Neuritis is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis.
    Neurology. 2022 Aug 2. pii: WNL.0000000000200970.
    PubMed     Abstract available
    
    
    June 2022
100. KENNEY RC, Liu M, Hasanaj L, Joseph B, et al
     The Role of OCT Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis.
     Neurology. 2022 Jun 28. pii: WNL.0000000000200883.
     PubMed     Abstract available
     
     
     
101. TOOSY AT, Eshaghi A
     Machine Learning Utility for Optical Coherence Tomography in Multiple Sclerosis: Is the Future Now?
     Neurology. 2022 Jun 28. pii: WNL.0000000000200862.
     PubMed    
     
     
     
102. FREEDMAN MS, Pozzilli C, Havrdova EK, Lemle A, et al
     Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results from Randomized Phase 2b Core and Extension Studies.
     Neurology. 2022 Jun 6. pii: WNL.0000000000200606.
     PubMed     Abstract available
     
     
     May 2022
103. SOTIRCHOS ES, Vasileiou ES, Filippatou AG, Fitzgerald KC, et al
     Association of Serum Neurofilament Light Chain With Inner Retinal Layer Thinning in Multiple Sclerosis.
     Neurology. 2022 May 26. pii: WNL.0000000000200778.
     PubMed     Abstract available
     
     
     
104. GRAVES J
     Identifying Multiple Sclerosis Activity: Do the Eyes Have It?
     Neurology. 2022 May 26. pii: WNL.0000000000200903.
     PubMed    
     
     
     
105. YANG JH, Graves JS
     Cancer Screening in Patients With Multiple Sclerosis: Are We Doing Enough?
     Neurology. 2022;98:737-738.
     PubMed    
     
     
     
106. LANGER-GOULD AM, Gonzales EG, Smith JB, Li BH, et al
     Racial and Ethnic Disparities in Multiple Sclerosis Prevalence.
     Neurology. 2022;98:e1818-e1827.
     PubMed     Abstract available
     
     
     
107. GROOME PA, Webber C, Maxwell CJ, McClintock C, et al
     Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer.
     Neurology. 2022;98:e1798-e1809.
     PubMed     Abstract available
     
     
     April 2022
108. YANG JH, Graves JS
     Cancer Screening in Patients With Multiple Sclerosis: Are We Doing Enough?
     Neurology. 2022 Apr 28. pii: WNL.0000000000200366.
     PubMed    
     
     
     
109. HAMILTON R, Ciccarelli O
     Multiple Sclerosis Incidence in Black Patients: It's Time to Do Away With a Racial Medical Myth.
     Neurology. 2022 Apr 28. pii: WNL.0000000000200309.
     PubMed    
     
     
     
110. LANGER-GOULD AM, Gonzales EG, Smith JB, Li BH, et al
     Racial and Ethnic Disparities in Multiple Sclerosis Prevalence.
     Neurology. 2022 Apr 28. pii: WNL.0000000000200151.
     PubMed     Abstract available
     
     
     
111. GROOME PA, Webber C, Maxwell CJ, McClintock C, et al
     Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer.
     Neurology. 2022 Apr 28. pii: WNL.0000000000200163.
     PubMed     Abstract available
     
     
     
112. ROTSTEIN D, Solomon JM, Sormani MP, Montalban X, et al
     Association of No Evidence of Disease Activity With No Long-term Disability Progression in Multiple Sclerosis: A Systematic Review and Meta-analysis.
     Neurology. 2022 Apr 26. pii: WNL.0000000000200549.
     PubMed     Abstract available
     
     
     
113. OKAI AF, Howard AM, Williams MJ, Brink JD, et al
     Advancing Care and Outcomes for African American Patients With Multiple Sclerosis.
     Neurology. 2022 Apr 25. pii: WNL.0000000000200791.
     PubMed     Abstract available
     
     
     
114. PORTACCIO E, Bellinvia A, Razzolini L, Pasto L, et al
     Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.
     Neurology. 2022;98:e1626-e1636.
     PubMed     Abstract available
     
     
     
115. BEBO B, Cintina I, LaRocca N, Ritter L, et al
     Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
     Neurology. 2022 Apr 13. pii: WNL.0000000000200150.
     PubMed     Abstract available
     
     
     
116. OSTKAMP P, Schwab N
     Effects of Latitude and Sunlight on Multiple Sclerosis Severity: Two Peas in a Pod?
     Neurology. 2022 Apr 11. pii: WNL.0000000000200105.
     PubMed    
     
     
     
117. VITKOVA M, Diouf I, Malpas C, Horakova D, et al
     Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.
     Neurology. 2022 Apr 11. pii: WNL.0000000000200545.
     PubMed     Abstract available
     
     
     
118. LEPPERT D, Kropshofer H, Haring DAA, Dahlke F, et al
     Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
     Neurology. 2022 Apr 4. pii: WNL.0000000000200258.
     PubMed     Abstract available
     
     
     March 2022
119. BOURDETTE D, Sormani MP
     Thinking Anew: Accelerating Clinical Trials of New Therapies for Progressive Multiple Sclerosis.
     Neurology. 2022 Mar 23. pii: WNL.0000000000200597.
     PubMed    
     
     
     
120. LI V, Leurent B, Barkhof F, Braisher M, et al
     Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis.
     Neurology. 2022 Mar 23. pii: WNL.0000000000200604.
     PubMed     Abstract available
     
     
     
121. BRIDEL C, Killestein J, Teunissen C
     Author Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2022;98:471.
     PubMed    
     
     
     
122. KROPSHOFER H, Haring DA, Kappos L, Leppert D, et al
     Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2022;98:470-471.
     PubMed    
     
     
     
123. LEWIS A, Galetta S
     Editors' Note: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2022;98:470.
     PubMed    
     
     
     
124. SIMMONS SB, Ontaneda D
     Slowly Expanding Lesions: A New Target for Progressive Multiple Sclerosis Trials?
     Neurology. 2022 Mar 11. pii: WNL.0000000000200230.
     PubMed    
     
     
     
125. CALVI A, Carrasco FP, Tur C, Chard DT, et al
     Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis.
     Neurology. 2022 Mar 11. pii: WNL.0000000000200144.
     PubMed     Abstract available
     
     
     
126. HAMILTON RH, Ciccarelli O
     Non-White Participants Matter in White Matter Disease Studies: The Importance of Diversity in Multiple Sclerosis Clinical Trials.
     Neurology. 2022;98:345-346.
     PubMed    
     
     
     February 2022
127. LIE IA, Weeda MM, Mattiesing RM, Mol MAE, et al
     Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis: A Systematic Review.
     Neurology. 2022 Feb 16. pii: WNL.0000000000200006.
     PubMed     Abstract available
     
     
     
128. MCELWEE DECKER B, Thibault D, Davis KA, Willis AW, et al
     Population-Based Study of Nonelective Postpartum Readmissions in Women With Stroke, Migraine, Multiple Sclerosis, and Myasthenia Gravis.
     Neurology. 2022 Feb 15. pii: WNL.0000000000200007.
     PubMed     Abstract available
     
     
     
129. HACOHEN Y, Ciccarelli O
     New Evidence for EBV Infection as a Cause of Multiple Sclerosis.
     Neurology. 2022 Feb 10. pii: WNL.0000000000200243.
     PubMed    
     
     
     
130. TORTORELLA C, Aiello A, Gasperini C, Agrati C, et al
     Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
     Neurology. 2022;98:e541-e554.
     PubMed     Abstract available
     
     
     January 2022
131. ONUORAH HM, Charron O, Meltzer E, Montague A, et al
     Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of Multiple Sclerosis DMTs: A Systematic Review.
     Neurology. 2022 Jan 19. pii: WNL.0000000000013230.
     PubMed     Abstract available
     
     
     
132. CUTTER GR, Koch MW
     Multiple Sclerosis Diagnostic Criteria: Moving Ahead or Walking in Place?
     Neurology. 2022;98:12-13.
     PubMed    
     
     
     
133. FILIPPI M, Preziosa P, Meani A, Dalla Costa G, et al
     Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study.
     Neurology. 2022;98:e1-e14.
     PubMed     Abstract available
     
     
     December 2021
134. MIRZA AI, Zhu F, Knox N, Forbes JD, et al
     Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome.
     Neurology. 2021 Dec 22. pii: WNL.0000000000013245.
     PubMed     Abstract available
     
     
     
135. SEBASTIAN P, Cherbuin N, Barcellos LF, Roalstad S, et al
     Association Between Time Spent Outdoors and Risk of Multiple Sclerosis.
     Neurology. 2021 Dec 8. pii: WNL.0000000000013045.
     PubMed     Abstract available
     
     
     
136. GRAVES JS, Killestein J
     Reading the "T" Leaves of COVID-19 Vaccine Responses in Multiple Sclerosis.
     Neurology. 2021 Dec 8. pii: WNL.0000000000013166.
     PubMed    
     
     
     October 2021
137. TINTORE M, Cobo-Calvo A, Carbonell P, Arrambide G, et al
     Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome.
     Neurology. 2021;97:e1641-e1652.
     PubMed     Abstract available
     
     
     
138. AA HOGLUND RA, Meyer HE, Stigum H, Torkildsen O, et al
     Association of Body Mass Index in Adolescence and Young Adulthood and Long-term Risk of Multiple Sclerosis: A Population-Based Study.
     Neurology. 2021 Oct 25. pii: WNL.0000000000012957.
     PubMed     Abstract available
     
     
     
139. KALINCIK T, Tremlett H, Ascherio A
     High BMI In Youths as a Modifiable Risk Factor for Multiple Sclerosis: Weighing Up the Evidence.
     Neurology. 2021 Oct 25. pii: WNL.0000000000012966.
     PubMed    
     
     
     
140. JANDRIC D, Lipp I, Paling D, Rog D, et al
     Mechanisms of Network Changes in Cognitive Impairment in Multiple Sclerosis.
     Neurology. 2021 Oct 14. pii: WNL.0000000000012834.
     PubMed     Abstract available
     
     
     
141. SIMPSON-YAP S, De Brouwer E, Kalincik T, Rijke N, et al
     Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
     Neurology. 2021 Oct 5. pii: WNL.0000000000012753.
     PubMed     Abstract available
     
     
     
142. KILLESTEIN J, Schoonheim MM, Voskuhl RR
     B-Cell Depletion and COVID-19 Severity in Multiple Sclerosis: Remaining Challenges.
     Neurology. 2021 Oct 5. pii: WNL.0000000000012754.
     PubMed    
     
     
     
143. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
     Association of Age at Onset With Gray Matter Volume and White Matter Microstructural Abnormalities in People With Multiple Sclerosis.
     Neurology. 2021 Oct 4. pii: WNL.0000000000012869.
     PubMed     Abstract available
     
     
     
144. HACOHEN Y, Eshaghi A
     Multiple Sclerosis in Children and Adults: Does Age Matter?
     Neurology. 2021 Oct 4. pii: WNL.0000000000012866.
     PubMed    
     
     
     
145. VRENKEN H, Jenkinson M, Pham D, Guttmann CRG, et al
     Opportunities for Understanding MS Mechanisms and Progression With MRI Using Large-Scale Data Sharing and Artificial Intelligence.
     Neurology. 2021 Oct 4. pii: WNL.0000000000012884.
     PubMed     Abstract available
     
     
     September 2021
146. MERLO D, Stankovich J, Bai C, Kalincik T, et al
     Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2021 Sep 23. pii: WNL.0000000000012850.
     PubMed     Abstract available
     
     
     
147. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
     Colorectal Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
     Neurology. 2021 Sep 15. pii: WNL.0000000000012634.
     PubMed     Abstract available
     
     
     
148. TOBIN O
     Early Diagnosis and Treatment is Associated With Improved Outcomes in Patients With Multiple Sclerosis.
     Neurology. 2021 Sep 14. pii: WNL.0000000000012738.
     PubMed    
     
     
     
149. MILLER JW
     Inflammation As A Target For Epilepsy Therapy: The Case of Natalizumab.
     Neurology. 2021 Sep 14. pii: WNL.0000000000012768.
     PubMed    
     
     
     
150. GOLDSCHMIDT C, Fox RJ
     Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression: Clear as Mud.
     Neurology. 2021 Sep 9. pii: WNL.0000000000012755.
     PubMed    
     
     
     
151. TOBIN WO, Kalinowska-Lyszczarz A, Weigand SD, Guo Y, et al
     Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes.
     Neurology. 2021 Sep 9. pii: WNL.0000000000012782.
     PubMed     Abstract available
     
     
     
152. BRIDEL C, Leurs CE, van Lierop ZY, van Kempen ZL, et al
     Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2021 Sep 9. pii: WNL.0000000000012752.
     PubMed     Abstract available
     
     
     
153. YEH EA, Bourdette D, Wiendl H
     Longer-Term Safety of B-Cell Therapy With Ocrelizumab in Multiple Sclerosis.
     Neurology. 2021 Sep 2. pii: WNL.0000000000012716.
     PubMed    
     
     
     
154. HAUSER SL, Kappos L, Montalban X, Craveiro L, et al
     Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.
     Neurology. 2021 Sep 2. pii: WNL.0000000000012700.
     PubMed     Abstract available
     
     
     
155. PALLADINO R, Chataway J, Majeed A, Marrie RA, et al
     Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality: A Population-Based Matched Cohort Study.
     Neurology. 2021 Sep 1. pii: WNL.0000000000012610.
     PubMed     Abstract available
     
     
     
156. SALTER A
     Assessment of Biological Interactions Between MS Status and Depression for Mortality.
     Neurology. 2021 Sep 1. pii: WNL.0000000000012615.
     PubMed    
     
     
     August 2021
157. RICE J, Xiang XM
     Comparing the Effectiveness of Therapies in People With Secondary Progressive Multiple Sclerosis.
     Neurology. 2021;97:e972-e974.
     PubMed    
     
     
     
158. DOBSON R, Salter A
     Differing Impact of Disease-Modifying Therapy on Relapse and Progression: Time to Consider Inflammation and Neuroprotection Separately?
     Neurology. 2021;97:407-408.
     PubMed    
     
     
     
159. KOCH MW, Mostert JP, Wolinsky JS, Lublin FD, et al
     Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2021 Aug 25. pii: WNL.0000000000012690.
     PubMed     Abstract available
     
     
     
160. KOCH MW, Mostert J, Zhang Y, Wolinsky JS, et al
     Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.
     Neurology. 2021 Aug 10. pii: WNL.0000000000012603.
     PubMed     Abstract available
     
     
     July 2021
161. SECHI E, Krecke KN, Messina SA, Buciuc M, et al
     Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
     Neurology. 2021 Jul 14. pii: WNL.0000000000012467.
     PubMed     Abstract available
     
     
     
162. NICHOLAS RS, Rhone EE, Mariottini A, Silber E, et al
     Autologous Haematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: a Real-world Case Series.
     Neurology. 2021 Jul 12. pii: WNL.0000000000012449.
     PubMed     Abstract available
     
     
     
163. HACOHEN Y, Kerr W, Waters P
     Intrathecal Production of MOG-IgG: Highlighting the Need for CSF Testing in Clinical Practice.
     Neurology. 2021;97:12-13.
     PubMed    
     
     
     June 2021
164. GRAY-RONCAL K, Fitzgerald K, Ryerson LZ, Charvet L, et al
     Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis.
     Neurology. 2021 Jun 30. pii: WNL.0000000000012362.
     PubMed     Abstract available
     
     
     
165. ROOS I, Leray E, Casey R, Horakova D, et al
     Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis.
     Neurology. 2021 Jun 30. pii: WNL.0000000000012354.
     PubMed     Abstract available
     
     
     
166. HUISKAMP M, Eijlers AJC, Broeders TAA, Pasteuning J, et al
     Longitudinal Network Changes and Conversion to Cognitive Impairment in Multiple Sclerosis.
     Neurology. 2021 Jun 7. pii: WNL.0000000000012341.
     PubMed     Abstract available
     
     
     
167. PREZIOSA P, Schoonheim MM
     Ongoing Axonal Injury in Chronic Active Lesions in Multiple Sclerosis: In-Vivo Quantification Using Serum Neurofilament.
     Neurology. 2021 Jun 4. pii: WNL.0000000000012331.
     PubMed    
     
     
     
168. CAMPBELL CREE BA, Arnold DL, Chataway J, Chitnis T, et al
     Secondary Progressive Multiple Sclerosis: New Insights.
     Neurology. 2021 Jun 4. pii: WNL.0000000000012323.
     PubMed     Abstract available
     
     
     
169. MAGGI P, Kuhle J, Schadelin S, van der Meer F, et al
     Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis.
     Neurology. 2021 Jun 4. pii: WNL.0000000000012326.
     PubMed     Abstract available
     
     
     May 2021
170. ROLLOT F, Fauvernier M, Uhry Z, Vukusic S, et al
     Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort.
     Neurology. 2021 May 19. pii: WNL.0000000000012224.
     PubMed     Abstract available
     
     
     
171. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
     Breast Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
     Neurology. 2021 May 19. pii: WNL.0000000000012127.
     PubMed     Abstract available
     
     
     
172. TOOSY AT, Kapur K, Nair KV
     Is OCT a Viable Tool to Monitor Disease-Modifying Treatments in RRMS Yet?
     Neurology. 2021;96:927-928.
     PubMed    
     
     
     
173. 
     Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
     Neurology. 2021 May 4. pii: WNL.0000000000011825.
     PubMed    
     
     
     
174. FOX RJ, Kryscio RJ
     A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis.
     Neurology. 2021;96:833-834.
     PubMed    
     
     
     
175. KOCH MW, Sage K, Kaur S, Kim J, et al
     Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.
     Neurology. 2021;96:e2313-e2322.
     PubMed     Abstract available
     
     
     
176. BAR-OR A, Herman A, Stokmaier D
     Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
     Neurology. 2021;96:870.
     PubMed    
     
     
     
177. HAHN N
     Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
     Neurology. 2021;96:870.
     PubMed    
     
     
     
178. SIEGLER JE, Galetta S
     Editors' Note: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
     Neurology. 2021;96:869.
     PubMed    
     
     
     April 2021
179. DUBESSY AL, Tezenas du Montcel S, Viala F, Assouad R, et al
     Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
     Neurology. 2021 Apr 30. pii: WNL.0000000000012120.
     PubMed     Abstract available
     
     
     
180. LEAVITT VM, Dobson R, Svennigsson A
     Perinatal Depression and Anxiety in Multiple Sclerosis: Treatable Distress.
     Neurology. 2021 Apr 28. pii: WNL.0000000000012101.
     PubMed    
     
     
     
181. SALAVISA M, Serrazina F, Pires P, Correia AS, et al
     Teaching Video NeuroImages: Infratentorial Multiple Sclerosis Relapse Presenting as Continuous Hemifacial Myokymia.
     Neurology. 2021 Apr 26. pii: WNL.0000000000012052.
     PubMed    
     
     
     
182. GASPERI C, Hapfelmeier A, Daltrozzo T, Schneider A, et al
     Systematic Assessment of Medical Diagnoses Preceding the First Diagnosis of Multiple Sclerosis.
     Neurology. 2021 Apr 26. pii: WNL.0000000000012074.
     PubMed     Abstract available
     
     
     
183. SOLOMON AJ, Ascherio A
     Early Diagnosis of Multiple Sclerosis: Further Evidence for Missed Opportunity.
     Neurology. 2021 Apr 26. pii: WNL.0000000000012087.
     PubMed    
     
     
     
184. 
     Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis.
     Neurology. 2021 Apr 23. pii: WNL.0000000000012021.
     PubMed    
     
     
     
185. EID K, Torkildsen OF, Aarseth J, Flemmen HO, et al
     Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study.
     Neurology. 2021 Apr 21. pii: WNL.0000000000012062.
     PubMed     Abstract available
     
     
     
186. YEH WZ, Widyastuti PA, Van der Walt A, Stankovich J, et al
     Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
     Neurology. 2021 Apr 20. pii: WNL.0000000000012084.
     PubMed     Abstract available
     
     
     
187. LAMBE J, Risher H, Filippatou AG, Murphy OC, et al
     Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.
     Neurology. 2021 Apr 7. pii: WNL.0000000000011933.
     PubMed     Abstract available
     
     
     March 2021
188. POIRION E, Tonietto M, Lejeune FX, Ricigliano VAG, et al
     Structural and Clinical Correlates of a Periventricular Gradient of Neuroinflammation in Multiple Sclerosis.
     Neurology. 2021 Mar 18. pii: WNL.0000000000011700.
     PubMed     Abstract available
     
     
     
189. LAMBE J, Fitzgerald KC, Murphy OC, Filippatou AG, et al
     Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple Sclerosis.
     Neurology. 2021 Mar 2. pii: WNL.0000000000011788.
     PubMed     Abstract available
     
     
     
190. VILLOSLADA P, Galetta SL, Toosy A
     Seeing the Finish Line: Can Baseline OCT Values Predict Long-Term Disability and Therapeutic Management in Multiple Sclerosis?
     Neurology. 2021 Mar 2. pii: WNL.0000000000011793.
     PubMed    
     
     
     
191. BANSAL P, Paul BS, Singh G
     Multiple Sclerosis Relapse Presenting As Sensorineural Hearing Loss.
     Neurology. 2021 Mar 2. pii: WNL.0000000000011796.
     PubMed    
     
     
     February 2021
192. KALAITZIDIS G, Calabresi PA
     Is Cerebrospinal Fluid Responsible for Innate Immune Cell Activation and Neurotoxicity in Multiple Sclerosis?
     Neurology. 2021 Feb 15. pii: WNL.0000000000011694.
     PubMed    
     
     
     
193. 
     Evaluation of Multiple Sclerosis Disability Outcome Measures Using Pooled Clinical Trial Data.
     Neurology. 2021 Feb 12. pii: WNL.0000000000011677.
     PubMed    
     
     
     January 2021
194. ALPING P, Burman J, Lycke J, Frisell T, et al
     Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Non-induction Therapies for Multiple Sclerosis.
     Neurology. 2021 Jan 29. pii: WNL.0000000000011545.
     PubMed     Abstract available
     
     
     
195. BROWNLEE WJ, Galetta S
     Optic Nerve in Multiple Sclerosis Diagnostic Criteria: An Aye to the Eyes?
     Neurology. 2021;96:139-140.
     PubMed    
     
     
     
196. SORMANI MP, Tur C, Barkhof F
     Ibudilast: A Paradigm Shift for Progressive Multiple Sclerosis?
     Neurology. 2021;96:141-142.
     PubMed    
     
     
     
197. BOFFA G, Massacesi L, Inglese M, Mariottini A, et al
     Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
     Neurology. 2021 Jan 20. pii: WNL.0000000000011461.
     PubMed     Abstract available
     
     
     
198. LEAVITT VM, Rocca M
     Siponimod for Cognition in Secondary Progressive Multiple Sclerosis: Thinking Through the Evidence.
     Neurology. 2021;96:91-92.
     PubMed    
     
     
     
199. ROCCA MA, Valsasina P, Meani A, Gobbi C, et al
     Association of Gray Matter Atrophy Patterns with Clinical Phenotype and Progression in Multiple Sclerosis.
     Neurology. 2021 Jan 13. pii: WNL.0000000000011494.
     PubMed     Abstract available
     
     
     
200. BOVIS F, Kalincik T, Lublin F, Cutter G, et al
     Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.
     Neurology. 2021;96:e214-e227.
     PubMed     Abstract available
     
     
     
201. SHAH S, Klassen BT, Flanagan EP
     Paroxysmal Dysarthria-Ataxia in Multiple Sclerosis.
     Neurology. 2021 Jan 5. pii: WNL.0000000000011498.
     PubMed    
     
     
     
202. KALINCIK T, Sormani MP, Tur C
     Has the Time Come to Revisit Our Standard Measures of Disability Progression in Multiple Sclerosis?
     Neurology. 2021;96:12-13.
     PubMed    
     
     
     December 2020
203. KALINCIK T, Diouf I, Sharmin S, Malpas C, et al
     Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
     Neurology. 2020 Dec 28. pii: WNL.0000000000011242.
     PubMed     Abstract available
     
     
     
204. 
     The 2013 clinical course descriptors for multiple sclerosis: A clarification.
     Neurology. 2020 Dec 22. pii: WNL.0000000000011198.
     PubMed    
     
     
     
205. BENEDICT RHB, Tomic D, Cree BA, Fox R, et al
     Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses.
     Neurology. 2020 Dec 16. pii: WNL.0000000000011275.
     PubMed     Abstract available
     
     
     
206. VIDAL-JORDANA A, Rovira A, Arrambide G, Otero-Romero S, et al
     Optic nerve region in multiple sclerosis diagnosis: the utility of visual evoked potentials.
     Neurology. 2020 Dec 16. pii: WNL.0000000000011339.
     PubMed     Abstract available
     
     
     
207. NAISMITH RT, Bermel RA, Coffey CS, Goodman AD, et al
     Effects of ibudilast on MRI measures in the phase 2 SPRINT-MS study.
     Neurology. 2020 Dec 2. pii: WNL.0000000000011314.
     PubMed     Abstract available
     
     
     
208. LANGESKOV-CHRISTENSEN M, Grondahl Hvid L, Nygaard MKE, Ringgaard S, et al
     Efficacy of high-intensity aerobic exercise on brain MRI measures in multiple sclerosis.
     Neurology. 2020 Dec 1. pii: WNL.0000000000011241.
     PubMed     Abstract available
     
     
     
209. BINZER S, Manouchehrinia A, Hillert J
     Author response: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
     Neurology. 2020;95:1026.
     PubMed    
     
     
     
210. BSTEH G, Berger T
     Reader response: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
     Neurology. 2020;95:1025-1026.
     PubMed    
     
     
     
211. GANESH A, Galetta S
     Editors' note: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
     Neurology. 2020;95:1025.
     PubMed    
     
     
     November 2020
212. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
     Cancer incidence and mortality rates in multiple sclerosis: A matched cohort study.
     Neurology. 2020 Nov 25. pii: WNL.0000000000011219.
     PubMed     Abstract available
     
     
     October 2020
213. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
     Reliability of outcome measures in clinical trials in secondary progressive multiple sclerosis.
     Neurology. 2020 Oct 26. pii: WNL.0000000000011123.
     PubMed     Abstract available
     
     
     
214. KLEIN DA COSTA B, Brant de Souza Melo R, Passos GRD, Gomes Meneses Sevilha Castro D, et al
     Unraveling B lymphocytes in CNS inflammatory diseases: Distinct mechanisms and treatment targets.
     Neurology. 2020;95:733-744.
     PubMed     Abstract available
     
     
     September 2020
215. ROTSTEIN DL, Yeh EA
     Could wider social networks prevent disability in MS and other neurologic disorders?
     Neurology. 2020;95:463-464.
     PubMed    
     
     
     August 2020
216. WALLIN MT
     Initial highly effective therapy for MS: A strong start.
     Neurology. 2020;95:e1114-e1116.
     PubMed    
     
     
     
217. OUTTERYCK O, Lopes R, Drumez E, Labreuche J, et al
     Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome.
     Neurology. 2020;95:e733-e744.
     PubMed     Abstract available
     
     
     
218. VAN KEMPEN ZLE, Hoogervorst ELJ, Wattjes MP, Kalkers NF, et al
     Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
     Neurology. 2020;95:e745-e754.
     PubMed     Abstract available
     
     
     
219. DIXON L, Shah S
     Teaching NeuroImages: Hypertrophic polyneuropathy.
     Neurology. 2020;95:e779-e780.
     PubMed    
     
     
     
220. NELSON LM, Bourdette D
     Two decades of research: Time to incorporate comorbidity management into the care of MS?
     Neurology. 2020;95:193-194.
     PubMed    
     
     
     
221. SALTER A, Kowalec K, Fitzgerald KC, Cutter G, et al
     Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial.
     Neurology. 2020;95:e446-e456.
     PubMed     Abstract available
     
     
     July 2020
222. KILLESTEIN J, Du Pasquier R, Hemmer B
     Vaccination in B-cell depleted MS patients.
     Neurology. 2020 Jul 29. pii: WNL.0000000000010378.
     PubMed    
     
     
     
223. CHEN JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, et al
     Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder.
     Neurology. 2020;95:e111-e120.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.